We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Sienna Biopharmaceuticals Inc | NASDAQ:SNNA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.1358 | 0.1382 | 0.1398 | 0 | 01:00:00 |
As filed with the Securities and Exchange Commission on December 11, 2019
Registration No. 333-219609
Registration No. 333-223689
Registration No. 333-230257
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-219609
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-223689
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-230257
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Sienna Biopharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware | 001-38155 | 27-3364627 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification Number) |
30699 Russell Ranch Road, Suite 140
Westlake Village, CA 91362
(818) 629-2256
(Address, including zip code and telephone number, including area code, of registrants principal executive office)
2010 Equity Incentive Plan, as amended
2017 Incentive Award Plan
2017 Employee Stock Purchase Plan
(Full title of the Plans)
Frederick C. Beddingfield III, M.D., Ph.D.
President and Chief Executive Officer
Sienna Biopharmaceuticals, Inc.
30699 Russell Ranch Road, Suite 140
Westlake Village, CA 91362
(818) 629-2256
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Alan C. Mendelson, Esq. | Timothy K. Andrews, Esq. | |
Brian J. Cuneo, Esq. | General Counsel and Secretary | |
Latham & Watkins LLP | Sienna Biopharmaceuticals, Inc. | |
140 Scott Drive | 30699 Russell Ranch Road, Suite 140 | |
Menlo Park, CA 94025 | Westlake Village, California 91362 | |
Telephone: (650) 328-4600 | Telephone: (818) 629-2256 | |
Facsimile: (650) 463-2600 | Facsimile: (818) 706-1214 |
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☒ | |||
Non-accelerated filer | ☐ | Smaller reporting company | ☒ | |||
Emerging growth company |
☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒
DEREGISTRATION OF UNSOLD SECURITIES
These Post-Effective Amendments (these Post-Effective Amendments) filed by Sienna Biopharmaceuticals, Inc., a Delaware corporation (the Registrant), relate to the following Registration Statements on Form S-8 (each, a Registration Statement, and collectively, the Registration Statements) filed by the Registrant with the U.S. Securities and Exchange Commission (the Commission).
|
Registration Statement on Form S-8 (No. 333-219609) pertaining to the registration of an aggregate of 2,692,268 shares of the Registrants common stock, $0.001 par value per share (Shares) issuable under the Registrants 2010 Equity Incentive Plan, as amended, 2017 Incentive Award Plan and 2017 Employee Stock Purchase Plan, which was filed with the Commission on August 1, 2017. |
|
Registration Statement on Form S-8 (No. 333-223689) pertaining to the registration of an aggregate of 1,037,007 Shares issuable under the Registrants 2017 Incentive Award Plan and 2017 Employee Stock Purchase Plan, which was filed with the Commission on March 15, 2018. |
|
Registration Statement on Form S-8 (No. 333-230257) pertaining to the registration of an aggregate of 1,058,855 Shares issuable under the Registrants 2017 Incentive Award Plan and 2017 Employee Stock Purchase Plan, which was filed with the Commission on March 14, 2019. |
The Registrant has informed the Nasdaq Hearings Panel (the Panel) regarding the results of the auction process of the Registrants assets, pursuant to the Panels decision letter dated November 12, 2019. The Registrant has requested to withdraw from the hearing process and that its common stock be suspended effective December 13, 2019 (the Delisting).
In connection with the Delisting, the Registrant has terminated any and all offerings pursuant to the Registration Statements. In accordance with undertakings made by the Registrant in the Registration Statements to remove from registration, by means of a post-effective amendment, any of the securities that remain unsold at the termination of the offerings, the Registrant hereby removes from registration all Shares registered but unsold under the Registration Statements as of the date hereof.
SIGNATURE
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to be signed on its behalf by the undersigned, thereunto duly authorized, in Westlake Village, State of California, on December 11, 2019.
Sienna Biopharmaceuticals, Inc. |
||
By: | /s/ Timothy K. Andrews | |
Name: Timothy K. Andrews |
||
Title: General Counsel and Secretary |
1 Year Sienna Biopharmaceuticals Chart |
1 Month Sienna Biopharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions